

## S 637

### CURE High Drug Prices Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Feb 28, 2019

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Feb 28, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/senate-bill/637>

### Sponsor

**Name:** Sen. Blumenthal, Richard [D-CT]

**Party:** Democratic • **State:** CT • **Chamber:** Senate

### Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Harris, Kamala D. [D-CA]	D · CA		Feb 28, 2019
Sen. Klobuchar, Amy [D-MN]	D · MN		Feb 28, 2019
Sen. Merkley, Jeff [D-OR]	D · OR		Feb 28, 2019
Sen. Sanders, Bernard [I-VT]	I · VT		Feb 28, 2019
Sen. Schatz, Brian [D-HI]	D · HI		Feb 28, 2019

### Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Feb 28, 2019

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
116 HR 4158	Related bill	<b>Aug 5, 2019:</b> Referred to the Subcommittee on Health.

### Summary (as of Feb 28, 2019)

#### Combatting Unreasonable Rises and Excessively High Drug Prices Act or the CURE High Drug Prices Act

This bill prohibits price gouging by manufacturers of prescription drugs (including a combination of a drug, device, or biological product) that are covered by a federal health care program. The bill specifies percentage increases in price at which price gouging is presumed.

## Actions Timeline

---

- **Feb 28, 2019:** Introduced in Senate
- **Feb 28, 2019:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.